ReviewMicrobial biotechnology2020
Consolidated bioprocessing for butanol production of cellulolytic Clostridia: development and optimization.
Review in Microbial biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 46 citations in OpenAlex.
- Grey-box modeling framework for consolidated bioprocessing systems: an endpoint-guided approach.Bioresources and bioprocessing · 2026Article
- Artificial Intelligence in Biofuels: Progress, Trends, and Directions.Chemistry & biodiversity · 2026Review
- Improvement of arabinoxylan degradation in Clostridium saccharobutylicum DSM 13864Applied microbiology and biotechnology · 2025Article
- Improved consolidated bioprocessing for itaconic acid production by simultaneous optimization of cellulase and metabolic pathway of Neurospora crassa.Biotechnology for biofuels and bioproducts · 2024Article
- The potential of native and engineered Clostridia for biomass biorefining.Frontiers in bioengineering and biotechnology · 2024Review
- Current progress on engineering microbial strains and consortia for production of cellulosic butanol through consolidated bioprocessing.Microbial biotechnology · 2023Review
- Microbial pathways for advanced biofuel production.Biochemical Society transactions · 2022Review
- Synergy of Cellulase Systems betweenMicroorganisms · 2022Article
- Developing Clostridia as Cell Factories for Short- and Medium-Chain Ester Production.Frontiers in bioengineering and biotechnology · 2021Review
- Optimization of n-butanol synthesis in Lactobacillus brevis via the functional expression of thl, hbd, crt and ter.Journal of industrial microbiology & biotechnology · 2020Article
- Consolidated bioprocessing for butanol production of cellulolytic Clostridia: development and optimization.Microbial biotechnology · 2020Review
- Gene coexpression network analysis reveals a novel metabolic mechanism ofBiotechnology for biofuels · 2020Article
- Synthetic Biology Tools for Genome and Transcriptome Engineering of SolventogenicFrontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Butanol is an important bulk chemical, as well as a promising renewable gasoline substitute, that is commonly produced by solventogenic Clostridia. The main cost of cellulosic butanol fermentation is caused by cellulases that are required to saccharify lignocellulose, since solventogenic Clostridia cannot efficiently secrete cellulases. However, cellulolytic Clostridia can natively degrade lignocellulose and produce ethanol, acetate, butyrate and even butanol. Therefore, cellulolytic Clostridia offer an alternative to develop consolidated bioprocessing (CBP), which combines cellulase production, lignocellulose hydrolysis and co-fermentation of hexose/pentose into butanol in one step. This review focuses on CBP advances for butanol production of cellulolytic Clostridia and various synthetic biotechnologies that drive these advances. Moreover, the efforts to optimize the CBP-enabling cellulolytic Clostridia chassis are also discussed. These include the development of genetic tools, pentose metabolic engineering and the improvement of butanol tolerance. Designer cellulolytic Clostridia or consortium provide a promising approach and resource to accelerate future CBP for butanol production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.